The Scottish Medicines Consortium (SMC) has approved funding for four new therapies to be made available via NHS Scotland, Pharma Times reported on Tuesday.
Shire's (LON: SHP) Revestive (teduglutide) has been accepted as a treatment for paediatric onset short bowel syndrome (SBS) in children aged one to 17 years. The glucagon-like peptide-2 (GLP-2) analogue has been licensed to treat patients in a stable condition once their intestine has adapted post-surgery. It was rejected by the National Institute for Health and Care Excellence last year.
Two medicines targeting hepatitis C were approved by SMC. The first is Gilead's (NASDAQ: GILD) pan-genotypic therapy Vosevi (sofosbuvir-velpatasvir-voxilaprevir) to be used as a treatment for hepatitis C in adults who have not responded to previous treatment with targeted anti-viral therapy. It has also been approved to be used in adults with hepatitis C genotype 3 who have not had previous targeted anti-viral treatment.
Gilead's Epclusa (sofosbuvir-velpatasvir) has also been recommended as a treatment for hepatitis C for patients with genotype 1 or 4 infection. This means that patients with all hepatitis C genotypes can receive treatment on the NHS in Scotland.
Finally, Sanofi's (EPA: SAN) Kevzara (sarilumab) was approved as a treatment for rheumatoid arthritis. The human monoclonal antibody binds to the interleukin-6 receptor (IL-6R) helping to reduce inflammation associated with the disease.
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
Hoth Therapeutics regains Nasdaq compliance
TME Pharma and SERI partner to advance NOX-E36 in ophthalmology through option framework agreement
Merry Life launches TML-6 global Phase II trial for Alzheimer's Disease
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
Vivoryon Therapeutics presents positive meta-analysis data for varoglutamstat
Sanofi's rilzabrutinib granted US orphan drug designation for sickle cell disease
Sanofi to acquire Blueprint Medicines in USD9.5bn rare disease deal
Genentech reports sustained two-year benefits from fenebrutinib in relapsing multiple sclerosis
RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis
TME Pharma announces extension of financial visibility to May 2026